Myriad Genetics (MYGN)
Nasdaq Market Closed
Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops genetic tests used to assess disease risk, support diagnosis, and guide treatment decisions. Its work sits at the intersection of genomics, laboratory testing, and clinical care, with a focus on helping physicians and patients use inherited and tumor-based genetic information in medical decision-making.
The company’s test menu spans several areas of healthcare. In oncology, products such as BRACAnalysis CDx, MyRisk, MyChoice CDx, Precise Tumor, and Prolaris help evaluate hereditary cancer risk, identify relevant biomarkers, or inform treatment choices for certain cancers. In women’s health and reproductive medicine, tests such as Foresight, Prequel, and SneakPeek address carrier screening, prenatal screening, and early pregnancy-related insights. GeneSight is used in mental health care to provide pharmacogenomic information that may help clinicians consider how a patient could respond to certain medications.
Myriad’s business is based largely on processing clinical samples, generating genetic data, interpreting results, and delivering reports that can be used by healthcare providers. The company operates mainly in the United States, which accounts for most of its revenue, while also serving select international markets.
Demand for Myriad’s services is linked to the adoption of genetic testing, insurance reimbursement, physician awareness, clinical guideline support, and advances in precision medicine. The company operates in a competitive diagnostics market where scientific validation, payer coverage, turnaround time, and ease of use are important. For investors, MYGN offers exposure to the expanding role of genetics in cancer care, reproductive health, mental health, and personalized medicine.
Last updated
- Market Cap
- 407.07M
- P/E
- —
- P/FCF
- —
- P/S
- 0.49
- Enterprise Value
- 402.97M
- Sector
- Health Care
- Industry
- In Vitro and In Vivo Diagnostic Substances
- Address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Decoding Our DNA: The Human Impact Behind SNP Genotyping’s USD 19.48 Billion Growth by 2034
Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights
Reproductive Genetics Market Size to Reach USD 16.67 Billion in 2032 Amid Increasing Demand for Genetic Testing
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
Genetic Material Market Size, Trends and Top Companies (2025 – 2034 Forecast Period)
Global Liquid Biopsy Market Set to Reach USD 7.05 Billion by 2030 | MarketsandMarkets™
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - Precision Medicine and Early Relapse Detection Drive MRD Testing Demand Worldwide
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection
Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™.
Pancreatic Cancer Diagnostic Market to Reach $3.2 billion, Globally, by 2035 at 5.9% CAGR: Allied Market Research
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 407.07M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 402.97M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.21
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.49
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -32.76
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 0.49
- EPS
- -4.23
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 169.61
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -13.3M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -118.52%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -59.36%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.36
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.4
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.19
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.96
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.82M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 4.31
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 200.4M | 209.8M | 205.7M | 213.1M | 195.9M |
| Gross profit | 137.6M | 146.8M | 143.8M | 151.8M | 134.2M |
| Operating income | -30.7M | -5.7M | -23.3M | -329.2M | -29M |
| EBITDA | -12.8M | 9.6M | -10.7M | 1.6M | -14.6M |
| Net income | -34.1M | -7.9M | -27.4M | -330.5M | -100K |
| Basic EPS | -0.36 | -0.07 | -0.29 | -3.57 | — |
| Diluted EPS | -0.36 | -0.07 | -0.29 | -3.57 | — |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 673.7M | 706.6M | 728.1M | 677.3M | 1.01B |
| Total liabilities | 336.3M | 338.6M | 355.3M | 289.2M | 301.2M |
| Total equity | 337.4M | 368M | 372.8M | 388.1M | 704.9M |
| Cash & equivalents | 124.4M | 149.6M | 145.4M | 74.4M | 91.8M |
| Current assets | 312.8M | 332.6M | 344.8M | 284.3M | 287.2M |
| Current liabilities | 130.2M | 133.8M | 148M | 199.9M | 151.1M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -15.7M | 10.6M | 21.1M | -13.6M | -16.3M |
| Investing cash flow | -6.5M | -6M | -6.2M | -6.9M | -8.3M |
| Financing cash flow | -3M | -8.2M | 56.2M | 2.6M | 13.6M |
| Change in cash | -25.3M | -3.5M | 71.1M | -17.3M | -10.9M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 3 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Jampa Raj | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Bisaro Paul | View Filing | |
| edgar index | SCHEDULE 13G — MYRIAD GENETICS INC | View Filing | |
| edgar index | 10-Q — MYRIAD GENETICS INC | View Filing | |
| edgar index | 8-K — MYRIAD GENETICS INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Donnelly Brian J | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | DEF 14A — MYRIAD GENETICS INC | View Filing | |
| edgar index | DEFA14A — MYRIAD GENETICS INC | View Filing | |
| edgar index | ARS — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Verratti Mark | View Filing | |
| form 4 | Form 4 — Muzzey Dale | View Filing | |
| edgar index | SCHEDULE 13G/A — MYRIAD GENETICS INC | View Filing | |
| edgar index | SCHEDULE 13G/A — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Verratti Mark | View Filing | |
| form 4 | Form 4 — Muzzey Dale | View Filing | |
| form 4 | Form 4 — Wheeler Benjamin Richard | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Verratti Mark | View Filing | |
| form 4 | Form 4 — Verratti Mark | View Filing | |
| form 4 | Form 4 — Haas Kevin Richard | View Filing | |
| form 4 | Form 4 — Haas Kevin Richard | View Filing | |
| form 4 | Form 4 — Muzzey Dale | View Filing | |
| form 4 | Form 4 — Muzzey Dale | View Filing | |
| form 4 | Form 4 — Wheeler Benjamin Richard | View Filing | |
| form 4 | Form 4 — Wheeler Benjamin Richard | View Filing | |
| form 4 | Form 4 — Solaiman Shereen | View Filing | |
| form 4 | Form 4 — Verratti Mark | View Filing | |
| form 4 | Form 4 — Raha Samraat S. | View Filing | |
| form 4 | Form 4 — Haas Kevin Richard | View Filing | |
| form 4 | Form 4 — Muzzey Dale | View Filing | |
| form 4 | Form 4 — Wheeler Benjamin Richard | View Filing | |
| form 4 | Form 4 — Solaiman Shereen | View Filing | |
| form 4 | Form 4 — Verratti Mark | View Filing | |
| form 4 | Form 4 — Raha Samraat S. | View Filing | |
| form 4 | Form 4 — Haas Kevin Richard | View Filing | |
| form 4 | Form 4 — Fox Jennifer Lynne | View Filing | |
| form 4 | Form 4 — Muzzey Dale | View Filing | |
| form 4 | Form 4 — Wheeler Benjamin Richard | View Filing | |
| form 4 | Form 4 — Solaiman Shereen | View Filing | |
| form 4 | Form 4 — Verratti Mark | View Filing | |
| form 4 | Form 4 — Raha Samraat S. | View Filing | |
| form 4 | Form 4 — Fox Jennifer Lynne | View Filing | |
| form 4 | Form 4 — Muzzey Dale | View Filing | |
| form 4 | Form 4 — Donnelly Brian J | View Filing | |
| form 4 | Form 4 — Wheeler Benjamin Richard | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Raha Samraat S. | View Filing | |
| edgar index | 424B3 — MYRIAD GENETICS INC | View Filing | |
| edgar index | EFFECT — MYRIAD GENETICS INC | View Filing | |
| edgar index | CORRESP — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Solaiman Shereen | View Filing | |
| edgar index | UPLOAD — MYRIAD GENETICS INC | View Filing | |
| edgar index | 4 — MYRIAD GENETICS INC | View Filing | |
| form 4 | Form 4 — Phanstiel S. Louise | View Filing | |
| form 4 | Form 4 — Phanstiel S. Louise | View Filing | |
| form 4 | Form 4 — Phanstiel S. Louise | View Filing | |
| form 4 | Form 4 — Phanstiel S. Louise | View Filing |